BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Stock Competitors & Peer Comparison
See BMRN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BMRN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BMRN | $60.02 | -0.92% | 11.6B | 28.86 | $2.08 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
BMRN vs VRTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas VRTX's P/E ratio is 25.35. In terms of profitability, BMRN's ROE is +0.04%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, BMRN is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
BMRN vs REGN Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas REGN's P/E ratio is 16.71. In terms of profitability, BMRN's ROE is +0.04%, compared to REGN's ROE of +0.18%. Regarding short-term risk, BMRN is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
BMRN vs VRNA Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas VRNA's P/E ratio is -102.80. In terms of profitability, BMRN's ROE is +0.04%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, BMRN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
BMRN vs ARGX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ARGX's P/E ratio is 78.75. In terms of profitability, BMRN's ROE is +0.04%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, BMRN is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
BMRN vs SGEN Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BMRN's ROE is +0.04%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BMRN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
BMRN vs RVMDW Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, BMRN's ROE is +0.04%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, BMRN is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
BMRN vs RVMD Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas RVMD's P/E ratio is -26.52. In terms of profitability, BMRN's ROE is +0.04%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, BMRN is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
BMRN vs ONC Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ONC's P/E ratio is 70.70. In terms of profitability, BMRN's ROE is +0.04%, compared to ONC's ROE of +0.12%. Regarding short-term risk, BMRN is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
BMRN vs ALNY Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ALNY's P/E ratio is 37.02. In terms of profitability, BMRN's ROE is +0.04%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, BMRN is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
BMRN vs ROIV Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ROIV's P/E ratio is -34.86. In terms of profitability, BMRN's ROE is +0.04%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, BMRN is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
BMRN vs INCY Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas INCY's P/E ratio is 16.06. In terms of profitability, BMRN's ROE is +0.04%, compared to INCY's ROE of +0.30%. Regarding short-term risk, BMRN is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
BMRN vs BNTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas BNTX's P/E ratio is -19.61. In terms of profitability, BMRN's ROE is +0.04%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, BMRN is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
BMRN vs UTHR Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas UTHR's P/E ratio is 19.10. In terms of profitability, BMRN's ROE is +0.04%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BMRN is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
BMRN vs MRNA Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas MRNA's P/E ratio is -6.73. In terms of profitability, BMRN's ROE is +0.04%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, BMRN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
BMRN vs INSM Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas INSM's P/E ratio is -17.15. In terms of profitability, BMRN's ROE is +0.04%, compared to INSM's ROE of -1.30%. Regarding short-term risk, BMRN is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
BMRN vs BGNE Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BMRN's ROE is +0.04%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, BMRN is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
BMRN vs DNA-WT Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BMRN's ROE is +0.04%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, BMRN is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
BMRN vs GMAB Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas GMAB's P/E ratio is 20.77. In terms of profitability, BMRN's ROE is +0.04%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, BMRN is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
BMRN vs NBIX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas NBIX's P/E ratio is 24.10. In terms of profitability, BMRN's ROE is +0.04%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, BMRN is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
BMRN vs JAZZ Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, BMRN's ROE is +0.04%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, BMRN is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
BMRN vs BBIO Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas BBIO's P/E ratio is -21.41. In terms of profitability, BMRN's ROE is +0.04%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, BMRN is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
BMRN vs ASND Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ASND's P/E ratio is -100.79. In terms of profitability, BMRN's ROE is +0.04%, compared to ASND's ROE of -56.42%. Regarding short-term risk, BMRN is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
BMRN vs EXEL Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas EXEL's P/E ratio is 15.88. In terms of profitability, BMRN's ROE is +0.04%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, BMRN is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
BMRN vs KRTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BMRN's ROE is +0.04%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BMRN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
BMRN vs ARWR Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ARWR's P/E ratio is -39.37. In terms of profitability, BMRN's ROE is +0.04%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, BMRN is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
BMRN vs TECH Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas TECH's P/E ratio is 37.16. In terms of profitability, BMRN's ROE is +0.04%, compared to TECH's ROE of +0.05%. Regarding short-term risk, BMRN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
BMRN vs RNAM Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas RNAM's P/E ratio is -17.39. In terms of profitability, BMRN's ROE is +0.04%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, BMRN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
BMRN vs AXSM Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas AXSM's P/E ratio is -56.92. In terms of profitability, BMRN's ROE is +0.04%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, BMRN is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
BMRN vs MDGL Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas MDGL's P/E ratio is -36.51. In terms of profitability, BMRN's ROE is +0.04%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, BMRN is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
BMRN vs SMMT Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas SMMT's P/E ratio is -8.14. In terms of profitability, BMRN's ROE is +0.04%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, BMRN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
BMRN vs KRYS Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas KRYS's P/E ratio is 45.60. In terms of profitability, BMRN's ROE is +0.04%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, BMRN is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
BMRN vs HALO Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas HALO's P/E ratio is 17.87. In terms of profitability, BMRN's ROE is +0.04%, compared to HALO's ROE of +1.26%. Regarding short-term risk, BMRN is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
BMRN vs CYTK Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CYTK's P/E ratio is -13.23. In terms of profitability, BMRN's ROE is +0.04%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, BMRN is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
BMRN vs RXDX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BMRN's ROE is +0.04%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BMRN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
BMRN vs ABVX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ABVX's P/E ratio is -65.48. In terms of profitability, BMRN's ROE is +0.04%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, BMRN is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
BMRN vs NUVL Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas NUVL's P/E ratio is -21.79. In terms of profitability, BMRN's ROE is +0.04%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, BMRN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
BMRN vs CRNX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CRNX's P/E ratio is -16.28. In terms of profitability, BMRN's ROE is +0.04%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, BMRN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
BMRN vs PTGX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas PTGX's P/E ratio is -75.49. In terms of profitability, BMRN's ROE is +0.04%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, BMRN is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
BMRN vs IMGN Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BMRN's ROE is +0.04%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, BMRN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
BMRN vs IONS Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas IONS's P/E ratio is -30.10. In terms of profitability, BMRN's ROE is +0.04%, compared to IONS's ROE of -1.11%. Regarding short-term risk, BMRN is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
BMRN vs PRAX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas PRAX's P/E ratio is -23.02. In terms of profitability, BMRN's ROE is +0.04%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, BMRN is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
BMRN vs SYRE Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas SYRE's P/E ratio is -47.27. In terms of profitability, BMRN's ROE is +0.04%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, BMRN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
BMRN vs KYMR Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas KYMR's P/E ratio is -29.29. In terms of profitability, BMRN's ROE is +0.04%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, BMRN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
BMRN vs ALKS Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ALKS's P/E ratio is 52.66. In terms of profitability, BMRN's ROE is +0.04%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, BMRN is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
BMRN vs BPMC Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BMRN's ROE is +0.04%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, BMRN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
BMRN vs APGE Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas APGE's P/E ratio is -30.97. In terms of profitability, BMRN's ROE is +0.04%, compared to APGE's ROE of -0.33%. Regarding short-term risk, BMRN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
BMRN vs CERE Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CERE's P/E ratio is -16.47. In terms of profitability, BMRN's ROE is +0.04%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BMRN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
BMRN vs TGTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas TGTX's P/E ratio is 17.88. In terms of profitability, BMRN's ROE is +0.04%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, BMRN is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
BMRN vs IMVT Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas IMVT's P/E ratio is -14.46. In terms of profitability, BMRN's ROE is +0.04%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, BMRN is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
BMRN vs PCVX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas PCVX's P/E ratio is -7.86. In terms of profitability, BMRN's ROE is +0.04%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, BMRN is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
BMRN vs IBRX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas IBRX's P/E ratio is -8.44. In terms of profitability, BMRN's ROE is +0.04%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, BMRN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
BMRN vs MTSR Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas MTSR's P/E ratio is -23.58. In terms of profitability, BMRN's ROE is +0.04%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, BMRN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
BMRN vs MRUS Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas MRUS's P/E ratio is -17.05. In terms of profitability, BMRN's ROE is +0.04%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, BMRN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
BMRN vs RYTM Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas RYTM's P/E ratio is -31.71. In terms of profitability, BMRN's ROE is +0.04%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, BMRN is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
BMRN vs ACLX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ACLX's P/E ratio is -28.27. In terms of profitability, BMRN's ROE is +0.04%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, BMRN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
BMRN vs COGT Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas COGT's P/E ratio is -18.45. In terms of profitability, BMRN's ROE is +0.04%, compared to COGT's ROE of -0.83%. Regarding short-term risk, BMRN is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
BMRN vs RETA Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas RETA's P/E ratio is -66.29. In terms of profitability, BMRN's ROE is +0.04%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BMRN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
BMRN vs MIRM Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas MIRM's P/E ratio is -7.78. In terms of profitability, BMRN's ROE is +0.04%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, BMRN is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
BMRN vs BLTE Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas BLTE's P/E ratio is -84.82. In terms of profitability, BMRN's ROE is +0.04%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, BMRN is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
BMRN vs ERAS Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ERAS's P/E ratio is -19.51. In terms of profitability, BMRN's ROE is +0.04%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, BMRN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
BMRN vs CGON Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CGON's P/E ratio is -30.55. In terms of profitability, BMRN's ROE is +0.04%, compared to CGON's ROE of -0.23%. Regarding short-term risk, BMRN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
BMRN vs CNTA Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CNTA's P/E ratio is -22.63. In terms of profitability, BMRN's ROE is +0.04%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, BMRN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
BMRN vs XENE Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas XENE's P/E ratio is -13.33. In terms of profitability, BMRN's ROE is +0.04%, compared to XENE's ROE of -0.49%. Regarding short-term risk, BMRN is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
BMRN vs LGND Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas LGND's P/E ratio is 34.48. In terms of profitability, BMRN's ROE is +0.04%, compared to LGND's ROE of +0.16%. Regarding short-term risk, BMRN is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
BMRN vs SRRK Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas SRRK's P/E ratio is -13.17. In terms of profitability, BMRN's ROE is +0.04%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, BMRN is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
BMRN vs PTCT Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas PTCT's P/E ratio is -29.19. In terms of profitability, BMRN's ROE is +0.04%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, BMRN is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
BMRN vs CDTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CDTX's P/E ratio is -19.77. In terms of profitability, BMRN's ROE is +0.04%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, BMRN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
BMRN vs ABCM Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BMRN's ROE is +0.04%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BMRN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
BMRN vs ISEE Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BMRN's ROE is +0.04%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BMRN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
BMRN vs APLS Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas APLS's P/E ratio is 38.35. In terms of profitability, BMRN's ROE is +0.04%, compared to APLS's ROE of +0.40%. Regarding short-term risk, BMRN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
BMRN vs TVTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas TVTX's P/E ratio is -254.05. In terms of profitability, BMRN's ROE is +0.04%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, BMRN is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
BMRN vs TERN Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas TERN's P/E ratio is -51.41. In terms of profitability, BMRN's ROE is +0.04%, compared to TERN's ROE of -0.20%. Regarding short-term risk, BMRN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
BMRN vs DFTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas DFTX's P/E ratio is N/A. In terms of profitability, BMRN's ROE is +0.04%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, BMRN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
BMRN vs DYN Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas DYN's P/E ratio is -7.82. In terms of profitability, BMRN's ROE is +0.04%, compared to DYN's ROE of -0.64%. Regarding short-term risk, BMRN is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
BMRN vs CRSP Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CRSP's P/E ratio is -9.39. In terms of profitability, BMRN's ROE is +0.04%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, BMRN is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
BMRN vs FOLD Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas FOLD's P/E ratio is -161.00. In terms of profitability, BMRN's ROE is +0.04%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, BMRN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
BMRN vs AKRO Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas AKRO's P/E ratio is -14.57. In terms of profitability, BMRN's ROE is +0.04%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, BMRN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
BMRN vs DNTH Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas DNTH's P/E ratio is -25.89. In terms of profitability, BMRN's ROE is +0.04%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, BMRN is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
BMRN vs ALPN Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BMRN's ROE is +0.04%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BMRN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
BMRN vs ACAD Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ACAD's P/E ratio is 12.68. In terms of profitability, BMRN's ROE is +0.04%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, BMRN is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
BMRN vs CAI Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CAI's P/E ratio is -86.19. In terms of profitability, BMRN's ROE is +0.04%, compared to CAI's ROE of +0.06%. Regarding short-term risk, BMRN is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
BMRN vs MANE Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas MANE's P/E ratio is -33.36. In terms of profitability, BMRN's ROE is +0.04%, compared to MANE's ROE of -0.84%. Regarding short-term risk, BMRN is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
BMRN vs OPT Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas OPT's P/E ratio is -1.52. In terms of profitability, BMRN's ROE is +0.04%, compared to OPT's ROE of +1.18%. Regarding short-term risk, BMRN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
BMRN vs PRTC Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas PRTC's P/E ratio is -3.78. In terms of profitability, BMRN's ROE is +0.04%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, BMRN is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
BMRN vs CELC Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CELC's P/E ratio is -22.15. In terms of profitability, BMRN's ROE is +0.04%, compared to CELC's ROE of -2.45%. Regarding short-term risk, BMRN is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
BMRN vs EWTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas EWTX's P/E ratio is -23.15. In terms of profitability, BMRN's ROE is +0.04%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, BMRN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
BMRN vs MRTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BMRN's ROE is +0.04%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BMRN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
BMRN vs ELVN Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ELVN's P/E ratio is -32.82. In terms of profitability, BMRN's ROE is +0.04%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, BMRN is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
BMRN vs CPRX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CPRX's P/E ratio is 12.30. In terms of profitability, BMRN's ROE is +0.04%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, BMRN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
BMRN vs RYZB Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BMRN's ROE is +0.04%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BMRN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
BMRN vs CBAY Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BMRN's ROE is +0.04%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BMRN is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
BMRN vs VKTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas VKTX's P/E ratio is -7.67. In terms of profitability, BMRN's ROE is +0.04%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, BMRN is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
BMRN vs DNLI Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas DNLI's P/E ratio is -7.99. In terms of profitability, BMRN's ROE is +0.04%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, BMRN is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
BMRN vs ORKA Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ORKA's P/E ratio is -49.75. In terms of profitability, BMRN's ROE is +0.04%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, BMRN is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
BMRN vs ADPT Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ADPT's P/E ratio is -41.80. In terms of profitability, BMRN's ROE is +0.04%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, BMRN is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
BMRN vs ALMS Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ALMS's P/E ratio is -7.39. In terms of profitability, BMRN's ROE is +0.04%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, BMRN is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
BMRN vs RCUS Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas RCUS's P/E ratio is -8.66. In terms of profitability, BMRN's ROE is +0.04%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, BMRN is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
BMRN vs SWTX Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BMRN's ROE is +0.04%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, BMRN is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for BMRN.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
BMRN vs ARQT Comparison August 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMRN stands at 11.6B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, BMRN is priced at $60.02 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMRN currently has a P/E ratio of 28.86, whereas ARQT's P/E ratio is -933.00. In terms of profitability, BMRN's ROE is +0.04%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, BMRN is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for BMRN.Check ARQT's competition here